Skip to content

Study on Alfentanil Used in Perioperative Pain Treatment of Patients Undergoing Cardiac Surgery by Cardiopulmonary Bypass

Study on Alfentanil Used in Perioperative Pain Treatment of Patients Undergoing Cardiac Surgery by Cardiopulmonary Bypass

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057510
Enrollment
Unknown
Registered
2022-03-14
Start date
2022-03-27
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Pain

Interventions

Alfentanil group:Alfentanil is used for analgesia during the perioperative period, 25 µg/kg at anesthesia induction, 12.5 µg/kg at skin incision, 15 µg/kg/h by continuous infusion for maintenance, and
Sufentanil group:Sufentanil is used for analgesia during the perioperative period, 0.5 µg/kg at anesthesia induction, 0.25 µg/kg at skin incision, 0.3 µg/kg/h by continuous infusion for maintenance,

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Elective heart valve surgery under extracorporeal circulation anesthesia (expected operation time is more than 2 hours, excluding small laparoscopic incision surgery); 2. Aged 18-65 years; 3. Grade II-IV cardiac function; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who could not complete the scale assessment; 2. A history of mental illness, chronic pain, alcohol or drug abuse; 3. Abnormal liver and kidney function (aminotransferase increased by more than 2 times); 4. A history of allergy to opioids; 5. BMI >=30kg/m^2; 6. Pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
Patient's satisfaction with analgesia 48 hours after surgery;

Secondary

MeasureTime frame
Pain score;Quality of Recovery;Adverse effects of opioids;

Countries

China

Contacts

Public ContactWang E

Xiangya Hospital, Central South University

ewang324@csu.edu.cn+86 188 7488 9950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026